ライフサイエンスコーパス: MBq

1 fic activities) of less than 20 pmol (>1,000 MBq/nmol) and 1 nmol (20 MBq/nmol) per mouse, respective

2 with specific activities greater than 1,000 MBq/nmol.

3 (82)Rb or (13)N-ammonia (1,100-3,000 MBq) was injected into the heart wall insert of an anthr

4 to a hypothetical minimum activity of 0.017 MBq of (124)I.

5 A 2,040-MBq self-shielded (68)Ge/(68)Ga generator provided metal

6 nistration of 366.3 +/- 14.8 (337.44-394.05) MBq of (18)F-fluciclovine.

7 radioembolization dosages from 46.3 to 105.1 MBq were infused, resulting in average absorbed doses of

8 OAEL for (177)Lu-DOTA-Fab-PEG24-EGF was 11.1 MBq (10 mug).

9 (111)In-cetuximab-F(ab')2 (5 mug, 28 +/- 6.1 MBq, 24 h after injection), followed by PET imaging with

10 Above 1 MBq, the median survival decreased linearly with injecte

11 MBq/200 pmol) versus high ( approximately 1 MBq/10 pmol) peptide amount of (177)Lu-NeoBOMB1, after w

12 l (68)Ga-NeoBOMB1 or a low ( approximately 1 MBq/200 pmol) versus high ( approximately 1 MBq/10 pmol)

13 Dosimetry estimates for 1 MBq of (225)Ac-PSMA-617 assuming a relative biologic eff

14 ues) acquired 30 h after administration of 1 MBq of (124)I.

15 red activities were 53-174 MBq (average, 107 MBq).

16 ution (7 d after tracer administration, 1.11 MBq/animal, n = 4-6/group) was performed in wild-type an

17 ter intravenous administration of 302 +/- 11 MBq of BAY 864367.

18 either 165 MBq (129-232 MBq, n = 10) or 110 MBq (82-116 MBq, n = 10), whereas control mice were inje

19 ed with 17.5 d (IQR, 5.5-22.5 d) for the 110-MBq and 41.0 d (IQR, 27.5-55.0) for the 165-MBg group.

20 on was reduced by 55% (P = 0.034) in the 110-MBq and by 88% (P < 0.01) in the 165-MBq group.

21 ination after injection of approximately 111 MBq of (18)F-FDG was performed.

22 rformed after injection of approximately 111 MBq of (64)Cu-ATSM.

23 MBq (129-232 MBq, n = 10) or 110 MBq (82-116 MBq, n = 10), whereas control mice were injected with ve

24 te-buffered saline, 6 MBq (213)Bi-IMP288, 12 MBq (213)Bi-IMP288, and 60 MBq (177)Lu-IMP288 was 22, 31

25 of the kidneys of mice treated with 17 or 12 MBq (213)Bi-IMP288 showed signs of tubular damage, indic

26 Conclusion:(177)Lu-PSMA-617 (120 MBq) and high specific activity resulted in the highest

27 (177)Lu-PSMA-617 (120 MBq) with high specific activity induced superior tumor

28 activity) or total activity (30, 60, or 120 MBq).

29 The median administered activity was 122 MBq in 53 (68)Ga-DOTATOC PET/CT studies, 198 MBq in 15 (

30 e were injected with either approximately 13 MBq/250 pmol (68)Ga-NeoBOMB1 or a low ( approximately 1

31 diac myocardial blood flow imaging were 3-14 MBq/kg, 1.5-4.0, 22-64 Mcps singles and 4-14 Mcps prompt

32 osmin (26 +/- 6 MBq), (123)I-MIBG (54 +/- 14 MBq), and a CZT camera.

33 (361 +/- 60 MBq) and high-dose (725 +/- 142 MBq) (99m)Tc-tetrofosmin scans were included, with 6-min

34 r than 99%, and specific activity of 111-148 MBq/mg.

35 riod at specific activities of less than 148 MBq/mg; however, specific activities up to 592 MBq/mg co

36 for up to 4 h after injection of 184 +/- 15 MBq of (18)F-TFB.

37 q/nmol; intermediate, 31 MBq/nmol; or low 15 MBq/nmol specific activity) or total activity (30, 60, o

38 tem after injection of (68)Ga-pentixafor (15 MBq/kg).

39 ble molar doses of TF2 and approximately 150 MBq of (68)Ga-IMP288 after different pretargeting time i

40 The highest organ-absorbed doses (for 150 MBq injected) were found in the urinary bladder wall (12

41 ncreased (99m)Tc-nanocolloid activity of 150 MBq to facilitate nodal detection against the gamma-prob

42 to 3.6 mSv, for a reference activity of 150 MBq.

43 The effective dose based on 150 MBq of (68)Ga-pentixafor was 2.3 mSv.

44 Patients received a single 150-MBq intravenous injection of (68)Ga-DOTATOC (15 mug of p

45 DOTATOC (15 mug of peptide) and 2 single 150-MBq intravenous injections of (68)Ga-OPS202 (15 mug of p

46 Patients received 2 single 150-MBq intravenous injections of (68)Ga-OPS202 3-4 wk apart

47 0 +/- 54 MBq) and rest (5 min; 1,024 +/- 153 MBq) fast SPECT MPI attenuation corrected (AC) by CT and

48 0 +/- 54 MBq) and rest (5 min; 1,024 +/- 153 MBq) fast SPECT MPI attenuation corrected (AC) by CT and

49 ents were injected intravenously with 90-158 MBq of (68)Ga-pentixafor (mean +/- SD, 134 +/- 25 MBq),

50 Patients received 137-163 MBq (mean +/- SD, 155.7 +/- 8 MBq) of (18)F-FET-betaAG-T

51 harmaceutical in a median dose of either 165 MBq (129-232 MBq, n = 10) or 110 MBq (82-116 MBq, n = 10

52 the 110-MBq and by 88% (P < 0.01) in the 165-MBq group.

53 l administered (177)Lu-DOTA-Bn activity, 167 MBq/mouse; estimated radiation absorbed dose to tumor, 1

54 , the effect of (213)Bi-IMP288 (6, 12, or 17 MBq) and (177)Lu-IMP288 (60 MBq) on tumor growth and sur

55 Mice receiving 17 MBq (213)Bi-IMP288 showed significant weight loss, resul

56 no-TOF PET, (124)I activities as high as 170 MBq may be warranted to obtain equal detectability.

57 The median administered activity was 170 MBq in 12 (111)In-pentetreotide SPECT/CT studies and 186

58 Administered activities were 53-174 MBq (average, 107 MBq).

59 Bq in 15 (18)F-FDOPA PET/CT studies, and 176 MBq in 13 (18)F-FDG PET/CT studies.

60 ous injection of (68)Ga-PSMA (mean dose, 176 MBq).

61 CZT camera, (99m)Tc-tetrofosmin (358 +/- 177 MBq) was administered and dual-isotope acquisition was p

62 (89)Zr-labeled radiotracers (mean dose, 180 MBq; range, 126-189 MBq) targeting prostate-specific mem

63 A mean activity of 184 MBq was administered to 10 patients with metastatic HER2

64 y administering doses in the range of 37-185 MBq as recommended incurrent guidelines.

65 from injected activities between 23 and 185 MBq.

66 In human PET studies, [(18) F]Nifene (185 MBq; <0.10 mug) was well tolerated with no adverse effec

67 ed volumes of 5 or 15 mL (n = 3 each) of 185 MBq of (99m)Tc-diethylenetriaminepentaacetic acid.

68 Patients received 185 MBq (5 mCi) of (89)Zr-IAB2M and Df-IAB2M at total mass d

69 ritical organ; the human target dose was 185 MBq.

70 11)In-pentetreotide SPECT/CT studies and 186 MBq in 10 (123)I-MIBG SPECT/CT studies.

71 otracers (mean dose, 180 MBq; range, 126-189 MBq) targeting prostate-specific membrane antigen (n = 7

72 Ultra-low-dose (<190 MBq) MPS even with short imaging times (<6 min) is feasi

73 MBq in 53 (68)Ga-DOTATOC PET/CT studies, 198 MBq in 15 (18)F-FDOPA PET/CT studies, and 176 MBq in 13

74 by defining malignant lesions in doses of 2 MBq/kgBW and the maximum dose image (gold standard).

75 ch simulated PET compared with the dose of 2 MBq/kgBW.

76 s were identified correctly with a dose of 2 MBq/kgBW; Likert scores did not differ significantly.

77 18)F-FDG PET/MRI might be possible down to 2 MBq/kgBW in oncologic whole-body examinations.

78 with a stable SUVpeak in all cases down to 2 MBq/kgBW.

79 tween 1.25 and 2.75 MBq/kgBW compared with 2 MBq/kgBW.

80 an 98% and specific activities of 326 +/- 20 MBq/nmol are obtained reproducibly.

81 er with 5 g 3-O-methylglucose (3-OMG) and 20 MBq (99m)Tc-sulfur colloid (total volume 200 mL), was gi

82 scalating injected activities (10, 15 and 20 MBq/kg) of (177)Lu-lilotomab satetraxetan and with diffe

83 of activity per body weight (10, 15, and 20 MBq/kg).

84 to the injected activity ( approximately 20 MBq for PET, 5-7 MBq for biodistribution).

85 han 20 pmol (>1,000 MBq/nmol) and 1 nmol (20 MBq/nmol) per mouse, respectively, uptake of (68)Ga-aqui

86 c point of view, an administered dose of 200 MBq for (64)CuCl2 translated into a 5.7-mSv effective do

87 hest after intravenous administration of 200 MBq of (18)F-fluoromethylcholine, followed by a whole-bo

88 f 3 mSv when the clinical target dose of 200 MBq was used.

89 The effective dose for a typical 200-MBq administration of (68)Ga-ABY-025 is 6.0 mSv for LD a

90 photodiode was illuminated by a standard 206 MBq (55)Fe radioisotope X-ray source and characterised o

91 Ga-NOTA-AE105 (154 +/- 59 MBq; range, 48-208 MBq).

92 Ga-NOTA-AE105 (154 +/- 59 MBq; range, 48-208 MBq).

93 y above the reported literature value of 220 MBq/mg.

94 or these 4 patients (mean injected dose, 231 MBq), the radiation exposure of a (68)Ga-PSMA-617 PET/CT

95 in a median dose of either 165 MBq (129-232 MBq, n = 10) or 110 MBq (82-116 MBq, n = 10), whereas co

96 activity recovery coefficient down to 0.240 MBq/mL with 30-min imaging time.

97 f (68)Ga-pentixafor (mean +/- SD, 134 +/- 25 MBq), and a series of 3 rapid multiple-bed-position whol

98 diameter, mice were injected with 0.75-2.25 MBq ( approximately 10 mug) of an engineered radiotracer

99 0 h after administration of approximately 25 MBq of (124)I and subsequently underwent imaging 5-10 d

100 1)In-DTPA-labetuzumab-IRDye800CW (10 mug, 25 MBq).

101 ry, received similar activities of about 250 MBq of (18)F-DCFPyL and (18)F-PSMA-1007 48 h apart and w

102 n PET acquisition 2 h after injection of 250 MBq of (18)F-AV-133, and the resulting images were quant

103 For an activity of 250 MBq, the absorbed doses in the bladder, liver, kidney, a

104 nhanced PET/CT after injection of 155 +/- 27 MBq of (68)Ga-PSMA ligand.

105 fter oral administration of approximately 28 MBq of (124)I-sodium iodide.

106 After injection of 189 +/- 3 MBq of (18)F-FIMX, 12 healthy volunteers underwent a dyn

107 enous injection of the tracer (198.3 +/- 3.3 MBq), 3 successive whole-body (vertex to mid thigh) PET/

108 mean +/- SEM) 4 h after injection of 7.3-9.3 MBq of (18)F-FVIIai and with an average maximum uptake i

109 , we do not recommend reducing doses below 3 MBq/kgBW in adults at this time.

110 Directly after administration of 3 MBq/kg of FCH, PET imaging was performed, followed by T1

111 In a tumor-bearing mouse injected with 3 MBq of [(213)Bi-DOTA,Tyr(3)]octreotate, tumor uptake cou

112 ompare mean (124)I RAIU levels versus mean 3-MBq (131)I RAIU levels (clinical standard).

113 n studies with (177)Lu-DOTA-JR11 (0.5 mug/30 MBq) resulted in the highest tumor radiation dose of 1.8

114 Conclusion While lower dose (300 MBq) BSGI has estimated benefit-to-radiation risk ratios

115 0 MBq at high, 62 MBq/nmol; intermediate, 31 MBq/nmol; or low 15 MBq/nmol specific activity) or total

116 derwent PET/CT after injection of 371 +/- 32 MBq of (18)F-FAZA.

117 with (64)Cu-labeled trastuzumab (0.016-0.368 MBq/mug, 67 nM) for 18 h versus the absorbed dose follow

118 A specific activity of 55.5 MBq/nmol (0.37 MBq/mug) was reproducibly obtained with [(89)Zr]Zr-darat

119 (89)Zr-bevacizumab (37 MBq) was administered intravenously 4 d before the scan.

120 c) mertiatide (MAG3) in the range of 300-370 MBq (approximately 8-10 mCi) contribute to image interpr

121 oses of (99m)Tc-MAG3 in the range of 300-370 MBq (approximately 8-10 mCi) do not affect the relative

122 g 5 min after injection of approximately 370 MBq of (18)F-fluciclovine.

123 45 (291 +/- 67 MBq) and 1-min (15)O-H2O (370 MBq) scans were obtained in 35 age-matched elderly subje

124 hest after intravenous administration of 370 MBq of (18)F-fluciclovine.

125 ognitive impairment, and 10 AD) received 370 MBq of flortaucipir F 18 and were imaged for 20 min begi

126 Dosimetry calculations predict that 370 MBq of (51)Mn in an adult human male would yield an effe

127 tive dose was estimated at 6.9 mSv for a 370-MBq (18)F-FTT dose in humans.

128 Our dosimetry data showed that a 370-MBq injection of (18)F-FAZA is safe for clinical use, si

129 uired as 4 x 5 min frames 80 min after a 370-MBq injection, were motion-corrected, averaged, and tran

130 Lower values ranging from 150 to 0.4 MBq/nmol were adjusted by addition of inactive compound

131 quisition for RVH and a high activity (303.4 MBq +/- 48.1) acquisition after administration of enalap

132 mouse at 5-min frames after injection of 7.4 MBq of (213)Bi-DTPA showed renal uptake and urinary clea

133 tion of 133.2-151.7 MBq (mean, 140.6 +/- 7.4 MBq) of (68)Ga-RM2 using a time-of-flight-enabled simult

134 ET/CT scanning after administration of 20-40 MBq of (124)I.

135 acers, for which an injected activity of 400 MBq corresponds to a total effective dose of approximate

136 Imaging was performed after injection of 400 MBq of (99m)Tc-CXCL8.

137 ganglioma/pheochromocytoma) received 148-444 MBq (4-12mCi) of (18)F-MFBG intravenously followed by se

138 t maximal dosages; 2 patients received a 444 MBq/kg dose of (131)I-MIBG plus a 0.15 mg/kg dose of ars

139 , patients received 5.5 MBq/kg (maximum, 485 MBq [0.15 mCi/kg; maximum, 12 mCi]) of (18)F-FDG with im

140 A hypothetical minimum activity of 0.5 MBq of (124)I obtained with iterative reconstruction app

141 whole-body PET/MRI examination from 3 to 0.5 MBq/kg of body weight (kgBW) in intervals of 0.25.

142 re injected intravenously with 232.4 +/- 1.5 MBq of (18)F-clofarabine.

143 re injected intravenously with 232.4 +/- 1.5 MBq of (18)F-clofarabine.

144 d a nonlinear increase, pronounced below 1.5 MBq/kgBW.

145 as 11.1 kcps and peaked at 20.8 kcps at 14.5 MBq.

146 0.65 mg/kg) (68)Ga-aquibeprin per mouse (3.5 MBq/nmol).

147 Treatment with 4.5 MBq (6 x 10(11) AuNP) of (177)Lu-T-AuNP or (177)Lu-NT-Au

148 to high radiochemical purity (>95%, 2.2-4.5 MBq/nmol).

149 icking imaging was achieved by injecting 5.5 MBq of 99mTc-anti-CD56 mAb in SCID mice bearing ARO tumo

150 In a separate session, patients received 5.5 MBq/kg (maximum, 485 MBq [0.15 mCi/kg; maximum, 12 mCi])

151 A specific activity of 55.5 MBq/nmol (0.37 MBq/mug) was reproducibly obtained with [

152 semiefficient doses of (177)Lu-DOTATATE (7.5 MBq, intravenously) or the nicotineamide phosphoribosylt

153 h after injection of (125)I-pentixafor (7.5 MBq/kg).

154 proliferation under optimised conditions (5 MBq/mL, 60 min).

155 invasive breast cancer received (18)F-FDG (5 MBq/kg) 45-60 min before surgery.

156 invasive breast cancer received (18)F-FDG (5 MBq/kg) 45-60 min before surgery.

157 osmin stress (5 min; mean +/- SD, 350 +/- 54 MBq) and rest (5 min; 1,024 +/- 153 MBq) fast SPECT MPI

158 osmin stress (5 min; mean +/- SD, 350 +/- 54 MBq) and rest (5 min; 1,024 +/- 153 MBq) fast SPECT MPI

159 nders received two doses of 15 mCi/m(2) (555 MBq/m(2)) (90)Y-epratuzumab tetraxetan administered 1 we

160 S5161 for a standard single injection of 555 MBq (15 mCi) will result in an effective dose equivalent

161 th the MR scan after injection of 199 +/- 58 MBq of (18)F-FDG.

162 T in a single-injection protocol (260 +/- 58 MBq of (18)F-FDG).

163 venous dose of (68)Ga-NOTA-AE105 (154 +/- 59 MBq; range, 48-208 MBq).

164 venous dose of (68)Ga-NOTA-AE105 (154 +/- 59 MBq; range, 48-208 MBq).

165 q/mg; however, specific activities up to 592 MBq/mg could be achieved with an incubation period.

166 small-animal SPECT/CT imaging (18.5 +/- 2.6 MBq) with 25 mug of (111)In-labeled ADCs were performed

167 assessed using (99m)Tc-tetrofosmin (26 +/- 6 MBq), (123)I-MIBG (54 +/- 14 MBq), and a CZT camera.

168 kg dose of (211)At-B10-CA12.10C12 (11.5-27.6 MBq/kg).

169 ps treated with phosphate-buffered saline, 6 MBq (213)Bi-IMP288, 12 MBq (213)Bi-IMP288, and 60 MBq (1

170 Low-dose (361 +/- 60 MBq) and high-dose (725 +/- 142 MBq) (99m)Tc-tetrofosmin

171 213)Bi-IMP288, 12 MBq (213)Bi-IMP288, and 60 MBq (177)Lu-IMP288 was 22, 31, 45, and 42 d, respectivel

172 88 (6, 12, or 17 MBq) and (177)Lu-IMP288 (60 MBq) on tumor growth and survival was assessed.

173 7 at different formulations for specific (60 MBq at high, 62 MBq/nmol; intermediate, 31 MBq/nmol; or

174 prostate cancer patients after a single 600-MBq (99m)Tc-methylene diphosphonate injection.

175 sulting in 2.68 mSv for a human subject (600-MBq dose).

176 ormulations for specific (60 MBq at high, 62 MBq/nmol; intermediate, 31 MBq/nmol; or low 15 MBq/nmol

177 after administration of approximately 30-63 MBq of (124)I.

178 enic trioxide; and 3 patients received a 666 MBq/kg dose of (131)I-MIBG plus a 0.15 mg/kg dose of ars

179 lanned treatment was (131)I-MIBG (444 or 666 MBq/kg) intravenously on day 1 plus arsenic trioxide (0.

180 Dynamic 60-min (18)F-AV45 (291 +/- 67 MBq) and 1-min (15)O-H2O (370 MBq) scans were obtained i

181 +/- 6.8 min) after injection of 133.2-151.7 MBq (mean, 140.6 +/- 7.4 MBq) of (68)Ga-RM2 using a time

182 ptying study followed, with ingestion of 3.7 MBq (0.1 mCi) of (111)In-DTPA in 300 mL of water.

183 count rate from a mouse-sized phantom at 3.7 MBq was 11.1 kcps and peaked at 20.8 kcps at 14.5 MBq.

184 activity ( approximately 20 MBq for PET, 5-7 MBq for biodistribution).

185 re than 97% and a specific activity of 3,700 MBq/mg and retaining biochemical integrity and binding a

186 A relatively low (124)I activity of 74 MBq (~1% of (131)I activity) is sufficient to achieve si

187 Patients underwent PET/CT with 74 MBq of (89)Zr-pertuzumab in a total antibody mass of 20-

188 ents received 740 MBq/1.7 m(2) (maximum, 740 MBq [20 mCi/1.7 m(2); maximum, 20 mCi]) of (11)C-methion

189 er a minimum 4-h fast, patients received 740 MBq/1.7 m(2) (maximum, 740 MBq [20 mCi/1.7 m(2); maximum

190 as stable over a range between 1.25 and 2.75 MBq/kgBW compared with 2 MBq/kgBW.

191 se biodistribution data (6 time points, 0.78 MBq/animal, n= 4/group).

192 with colorectal cancer received 36.9 +/- 0.8 MBq of (89)Zr-cetuximab within 2 h after administration

193 protocols using (18)F-DCFPyL (n = 62, 269.8 MBq, PET scan at 120 min after injection) or (68)Ga-PSMA

194 protocols using (18)F-DCFPyL (n = 62, 269.8 MBq, PET scan at 120 min after injection) or (68)Ga-PSMA

195 or up to 3 h after injection (357.2 +/- 48.8 MBq).

196 ceived 137-163 MBq (mean +/- SD, 155.7 +/- 8 MBq) of (18)F-FET-betaAG-TOCA.

197 yield (>87%), high specific activity (>/=9.8 MBq/nmol), and purity (>99%).

198 one using buffered eluate fractions (600-800 MBq, pH 2) of an SnO2-based generator, affording the rad

199 Dynamic PET imaging with 18F-FDG (7.7+/-0.9 MBq) was conducted.

200 received (89)Zr-bevacizumab (0.1 mg/kg; 0.9 MBq/kg) at least 2 wk after completing radiotherapy.

201 received (89)Zr-bevacizumab (0.1 mg/kg; 0.9 MBq/kg) at least 2 wk after completing radiotherapy.

202 tion) or (68)Ga-PSMA-HBED-CC (n = 129, 158.9 MBq, 60 min after injection).

203 tion) or (68)Ga-PSMA-HBED-CC (n = 129, 158.9 MBq, 60 min after injection).

204 d by PET imaging with (18)F-FDG (9.4 +/- 2.9 MBq, 1 h after injection).

205 isition after administration of 42.1 +/- 3.9 MBq of (18)F-FMISO by tail vein injection.

206 on was determined after a low activity (62.9 MBq +/- 40.7) baseline acquisition for RVH and a high ac

207 or), with an injected activity of 3.70/12.95 MBq, for (64)Cu-/(177)Lu-cetuximab, respectively.

208 d dose of (131)I-MIBG to blood was 0.134 cGy/MBq, well below myeloablative levels in all patients.

209 he peak sensitivity reached 1.3% (13,080 cps/MBq).

210 ghest tumor radiation dose of 1.8 +/- 0.7 Gy/MBq, 4.4 times higher than the highest tumor radiation d

211 he 10 3D PET systems if the maximum injected MBq/kg values are respected to limit peak dead-time loss

212 A sensitivity of 7.5 and 11.7 kcps/MBq at the center for tight and loose cuts, respectively

213 respectively, increased to 8.8 and 13.9 kcps/MBq, respectively, at a 10-cm radial offset.

214 /min in ratios varying from 1:37 to 1:592 mg:MBq at 37 degrees C to achieve optimal labeling.

215 doses of 0.17 +/- 0.04 and 0.51 +/- 0.06 mGy.MBq(-1), respectively.

216 eas the dose to the red marrow was 0.006 mGy/MBq.

217 , at 0.047 +/- 0.008 and 0.067 +/- 0.007 mGy/MBq for the 2- and 4-h voiding intervals, respectively.

218 mean total-body dose was 0.011 +/- 0.011 mGy/MBq, and the effective dose was 0.023 +/- 0.012 mSv/MBq.

219 l doses ranged from 6.29E-03 to 2.46E-02 mGy/MBq.

220 d liver exposure of 0.10, 0.65, and 0.06 mGy/MBq, respectively.

221 marrow was 0.13, 0.086, 0.33, and 0.068 mGy/MBq after rhTSH and 0.11, 0.14, 0.22, and 0.080 mGy/MBq

222 er rhTSH and 0.11, 0.14, 0.22, and 0.080 mGy/MBq after THW for each patient, respectively.

223 all, with median values of 1.37 and 1.12 mGy/MBq, respectively.

224 0 vs. 265 mGy/MBq; 10 pmol, 435 vs. 1393 mGy/MBq).

225 The liver received 0.70-1.15 mGy/MBq.

226 /MBq), and the heart wall (1.22 +/- 0.16 mGy/MBq), with an average effective dose of 0.54 +/- 0.07 mS

227 whole-body dose ranged from 0.08 to 0.17 mGy/MBq.

228 a mean absorbed dose of 0.186 +/- 0.195 mGy/MBq.

229 egnant mother ranges from 0.5E-2 to 4E-2 mGy/MBq.

230 r wall as the dose-limiting organ (0.200 mGy/MBq), whereas the dose to the red marrow was 0.006 mGy/M

231 an +/- SD) were the liver (1.75 +/- 0.21 mGy/MBq), the kidneys (1.27 +/- 0.28 mGy/MBq), and the heart

232 rsus the pancreas (200 pmol, 570 vs. 265 mGy/MBq; 10 pmol, 435 vs. 1393 mGy/MBq).

233 .21 mGy/MBq), the kidneys (1.27 +/- 0.28 mGy/MBq), and the heart wall (1.22 +/- 0.16 mGy/MBq), with a

234 d high absorbed tumor doses (median, 3.3 mGy/MBq) compared with the levels in normal organs.

235 arotid glands received higher doses (1.3 mGy/MBq) than kidneys (0.8 mGy/MBq).

236 dose estimates were 1.67, 1.36, and 0.32 mGy/MBq to liver, kidney, and marrow, respectively, with an

237 st than for the agonist (0.854 vs. 0.333 mGy/MBq for a 4-cm tumor).

238 inary bladder wall, with a dose of 0.406 mGy/MBq.

239 9 mGy/MBq for arm 1 (lilotomab+) and 1.5 mGy/MBq for arm 2 (lilotomab-).

240 d to the red marrow were 177-994 and 1-5 mGy/MBq from activity on the bone surfaces and from activity

241 en, with doses ranging from 1.54 to 3.60 mGy/MBq.

242 he source organs investigated, 0.16-0.79 mGy/MBq.

243 bed dose estimates were highest (0.3-0.8 mGy/MBq) in the lumbar CSF space.

244 er doses (1.3 mGy/MBq) than kidneys (0.8 mGy/MBq).

245 The mean absorbed doses to RM were 0.9 mGy/MBq for arm 1 (lilotomab+) and 1.5 mGy/MBq for arm 2 (li

246 The average fetal doses (mGy/MBq) with OLINDA/EXM 2.0 were 2.5E-02 in early pregnancy

247 The effective dose was 0.0326 +/- 0.0018 mSv/MBq.

248 0.003 mSv/MBq for LD and 0.028 +/- 0.002 mSv/MBq for HD.

249 labeled tracers, such as 0.021 +/- 0.003 mSv/MBq for (68)Ga-DOTATATE and (68)Ga-DOTATOC, mainly becau

250 Total effective dose was 0.030 +/- 0.003 mSv/MBq for LD and 0.028 +/- 0.002 mSv/MBq for HD.

251 le-body effective dose estimate of 0.003 mSv/MBq was observed.

252 were 0.013 +/- 0.004 and 0.014 +/- 0.004 mSv/MBq, respectively, depending on the voiding schedule.

253 bjects (mean +/- SD) was 0.029 +/- 0.004 mSv/MBq.

254 ith an effective dose estimate of 0.0045 mSv/MBq, resulting in 2.68 mSv for a human subject (600-MBq

255 46 mSv/MBq) and kidneys (0.029 +/- 0.009 mSv/MBq).

256 stimated human absorbed dose of 2.20E-01 mSv/MBq.

257 livary glands (parotids, 0.031 +/- 0.011 mSv/MBq; submandibular, 0.061 +/- 0.031 mSv/MBq).

258 d the effective dose was 0.023 +/- 0.012 mSv/MBq.

259 The effective dose was 0.015 mSv/MBq, leading to a radiation burden of 3 mSv when the cli

260 effective dose was estimated to be 0.017 mSv/MBq.

261 the effective dose from 0.0908 to 0.0184 mSv/MBq and decreased the uptake in the liver, bone marrow,

262 s than younger children (0.011 and 0.019 mSv/MBq, respectively; P < 0.0001).

263 d effective dose was 2.4E-02 +/- 0.2E-02 mSv/MBq, corresponding to 3.6 mSv, for a reference activity

264 The mean effective dose was 2.07E-02 mSv/MBq.

265 0.079 mSv/MBq), stomach (0.069 +/- 0.022 mSv/MBq), and salivary glands (parotids, 0.031 +/- 0.011 mSv

266 mSv/MBq; submandibular, 0.061 +/- 0.031 mSv/MBq).

267 ines were 0.082, 0.043, 0.042, and 0.035 mSv/MBq, respectively.

268 The effective dose was 0.043 mSv/MBq, resulting in an average of 4.6 mSv per patient.

269 terest were the bladder (0.102 +/- 0.046 mSv/MBq) and kidneys (0.029 +/- 0.009 mSv/MBq).

270 average effective dose of 0.54 +/- 0.07 mSv/MBq.

271 doses were the thyroid (0.135 +/- 0.079 mSv/MBq), stomach (0.069 +/- 0.022 mSv/MBq), and salivary gl

272 ose per patient was 0.9 mSv/MBq (SD, 0.3 mSv/MBq).

273 ided an effective dose of less than 0.30 mSv/MBq, with the gallbladder as the critical organ; the hum

274 ectively, with an effective dose of 0.41 mSv/MBq (1.5 rem/mCi).

275 mean effective dose per patient was 0.9 mSv/MBq (SD, 0.3 mSv/MBq).

276 doses in source organs ranged from 7.7 muGy.MBq(-1) in the brain to 12.7 muGy.MBq(-1) in the spleen.

277 m 7.7 muGy.MBq(-1) in the brain to 12.7 muGy.MBq(-1) in the spleen.

278 effective dose (+/-SD) was 4.5 +/- 0.5 muSv.MBq(-1)The effective dose of (11)C-GMOM is at the lower

279 Effective doses were 3.41 +/- 0.06 muSv/MBq for (11)C-elacidar and 3.62 +/- 0.11 muSv/MBq for (1

280 q (intravenous administration) and 18.1 muSv/MBq (oral administration).

281 Bq for (11)C-elacidar and 3.62 +/- 0.11 muSv/MBq for (11)C-tariquidar.

282 the effective dose was estimated at 17 muSv/MBq.

283 r wall as the dose-critical tissue (185 muSv/MBq), followed by the kidneys (23 muSv/MBq).

284 +/- 4.9, 31.0 +/- 2.4, and 20.9 +/- 5.2 muSv/MBq for the no-voiding, 2.5-h-voiding, and 1-h-voiding m

285 muSv/MBq), followed by the kidneys (23 muSv/MBq).

286 igands, the effective dose was about 23 muSv/MBq.

287 he liver (43.1 +/- 4.9 and 68.9 +/- 9.4 muSv/MBq in reference human male and female phantoms, respect

288 8.70 muSv/MBq), kidneys (9.56 +/- 2.46 muSv/MBq), liver (8.94 +/- 1.67 muSv/MBq), and spleen (9.49 +

289 acceptable, with effective doses of 9.5 muSv/MBq (intravenous administration) and 18.1 muSv/MBq (oral

290 ivalent was 6.9 +/- 0.6 and 8.7 +/- 0.6 muSv/MBq, respectively.

291 /- 2.46 muSv/MBq), liver (8.94 +/- 1.67 muSv/MBq), and spleen (9.49 +/- 3.89 muSv/MBq).

292 se for (11)C-nicotine was 5.44 +/- 0.67 muSv/MBq.

293 he total absorbed body dose was low (<7 muSv/MBq); the effective dose was estimated at 17 muSv/MBq.

294 he urinary bladder wall (14.68 +/- 8.70 muSv/MBq), kidneys (9.56 +/- 2.46 muSv/MBq), liver (8.94 +/-

295 67 muSv/MBq), and spleen (9.49 +/- 3.89 muSv/MBq).

296 of 54% per Gy of X-ray radiation and 15% per MBq/ml of 2-deoxy-2-[(18)F]-fluoro-d-glucose ([(18)F]FDG

297 erall absorbed dose to the normal organs per MBq of (131)I administered, between the 2 TSH stimulatio

298 n patients received 325 +/- 29 (mean +/- SD) MBq of the cyclotron-produced (99m)Tc-NaTcO4, whereas th

299 3)I-MIBG injection (191 +/- 41 [mean +/- SD] MBq).

300 The sites reported dosage by weight (MBq/kg), minimum and maximum dosages, and the activities